The recently published AUA practice guideline on Peyronie’s disease provides current clinical principles on diagnosis and treatment of a highly prevalent and clinically significant condition, according to the co-chair of the multidisciplinary panel that developed the guideline.
Findings from a retrospective study lend support to the idea that even in men with a Gleason 7 (3+4) biopsy score, prostate cancer may sometimes act like low-risk disease.
The test could be a step closer to personalized risk-based prostate cancer diagnostic programs, study authors say.
Researchers say they’ve uncovered a wide variation in costs to treat low-risk prostate cancer.
Movember is a global movement that leverages the power of the mustache to promote men's health. Hear from Brian Stork, MD as he shares insight into what Movember means for him and what you need to know.
“The best way to avoid overtreatment is to avoid overdiagnosis. MRI allows you to do that," says Mark Emberton, MD.
In this case study, a man in his fifth decade of life complained of right side testicular swelling that had persisted for 2 weeks. He reported no pain.
Other products highlighted in this slideshow include a trial system for incontinence therapy, a compact catheter, a wearable digital technology solution for continence care assessment and management, and laser fiber and sheath system.
Over the last 5 years, we have developed a comprehensive, multispecialty, hospital-based men's health center, and we believe that the following five elements are the keys to its success.
A prostate cancer vaccine and an infertility diagnostic tool are among the other pipeline products discussed in this round-up.
Don't count out men who have not recovered urinary and erectile function at 12 months after radical prostatectomy.
This slideshow presents a case study of a 30-year-old male with discomfort in left groin region due to mass/swelling for 1 year.
The Sonablate 450, SonaCare Medical’s high-intensity focused ultrasound (HIFU) device, has received FDA clearance for prostate tissue ablation.
New study findings from the Ronald Reagan UCLA Medical Center, Los Angeles add evidence supporting the potential for targeted magnetic resonance-ultrasound (MR-US) fusion biopsy to improve the diagnosis of prostate cancer. Learn more
Shock wave therapy has now been subjected to multiple randomized, placebo-controlled, and additional open-label studies in clinics worldwide, demonstrating impressive efficacy and safety.
In this interview, Peter L. Choyke, MD, discusses current methods of detecting biochemical recurrence with imaging, promising new techniques to localize recurrence, and cost considerations.
Phase II study results show that daily treatment with abiraterone acetate (ZYTIGA), 1,000 mg, plus prednisone, 5 mg was very effective in lowering PSA levels in men with non-metastatic castrate-resistant prostate cancer (CRPC) at high risk for metastasis. Learn more
Positron emission tomography with a 68Gallium-labeled ligand of prostate-specific membrane antigen (68Ga-HBED-PSMA-PET hybrid imaging) is a promising new diagnostic tool for staging prostate cancer, according to German urologists who presented their experience at the American Society of Clinical Oncology annual meeting in Chicago. Get results
Experience with low-intensity extracorporeal shock wave therapy from multinational clinical trials demonstrates it is a safe, effective, and well-tolerated treatment for erectile dysfunction, including in men who do not respond to an oral phosphodiesterase type-5 inhibitor, reported Robert Feldman, MD, at the AUA annual meeting in New Orleans.
Hear and get results from Neal Shore, MD, as he discusses with Crystal Murcia, PhD the surveys findings, explains why men aren’t speaking up about their prostate cancer symptoms, and urologists' role in assessing how patients are feeling.
The assay might help identify candidates for active surveillance, study authors say.
Economic, social, and cultural factors all have an impact on Americans’ access to effective infertility treatment, a new report states.
A new study underscores the long-term value of active surveillance for men with low- or very low-risk prostate cancer.
The opportunities for physicians in men’s health are tremendous. As with most career moves, blindly entering a field is ill advised. Rather, I recommend that the thoughtful young urologist carefully consider the following steps and pointers.
A novel treatment for the targeted removal of prostate tissue may soon be coming to a hospital near you. According to the results of a phase II study presented at the AUA annual meeting in New Orleans, Aquablation, a minimally invasive water ablation therapy, demonstrated efficient and precise resection of prostate tissue in patients with BPH.
